Peptide library
P140
Your guide to this compound.
Dose context
Human study context; not a personal regimen
The phase 2b trial compared 200 micrograms subcutaneously every two or four weeks with placebo, alongside standard care. Research context only.
How to read this information
Catalog ranges can describe approved labeling, clinical research or unverified reports. They are not interchangeable and do not select a personal dose.
Half-life
No human half-life verified in this snapshot. A long-acting description or trial interval is not a measured elimination half-life.
Species, route and formulation matter. Half-life does not define a safe dosing interval.
Routes and frequency in the catalog
Storage
Product-specific stability and storage instructions have not been verified. Study material and vendor vials cannot be assumed interchangeable.
Generic storage notes cannot establish a beyond-use date or sterility for a particular vial.
Preparation and reconstitution
No preparation recipe supplied. Use the exact licensed product instructions or the study pharmacy protocol, as applicable.